Biotech | October 22, 2021
Zydus announces update on a randomised trial of Saroglitazar Mg in NASH
Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders
